Literature DB >> 23504356

Pharmacotherapy for the core symptoms in autistic disorder: current status of the research.

Cristan Farmer1, Audrey Thurm, Paul Grant.   

Abstract

The current review covers extant literature on pharmacotherapy for core symptoms of autism. The core symptoms of autism include impairments in social interaction and communication, as well as the presence of restricted and repetitive behaviors. There are no known efficacious treatments for the core social symptoms, although effects on repetitive behaviors are indicated with some data. While studies of fenfluramine, secretin, opiates, and mood stabilizers generally find no effect, mixed results suggest more research is needed on antidepressants and atypical antipsychotics. Newer lines of research, including cholinergic and glutamatergic agents and oxytocin, will be of considerable interest in the future. However, research on the treatment of core symptoms is plagued by limitations in study design, statistical power, and other issues inherent to the study of treatments for autism (e.g., heterogeneity of the disorder) that continue to prevent the elucidation of efficacious treatments.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504356      PMCID: PMC3632301          DOI: 10.1007/s40265-013-0021-7

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  89 in total

Review 1.  Neurochemistry in the pathophysiology of autism.

Authors:  Christopher J McDougle; Craig A Erickson; Kimberly A Stigler; David J Posey
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

2.  Fenfluramine treatment of autism: UCLA collaborative study of 81 patients at nine medical centers.

Authors:  E R Ritvo; B J Freeman; A Yuwiler; E Geller; P Schroth; A Yokota; A Mason-Brothers; G J August; W Klykylo; B Leventhal
Journal:  Psychopharmacol Bull       Date:  1986

3.  The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism.

Authors:  C Lord; S Risi; L Lambrecht; E H Cook; B L Leventhal; P C DiLavore; A Pickles; M Rutter
Journal:  J Autism Dev Disord       Date:  2000-06

4.  An open trial of divalproex sodium in autism spectrum disorders.

Authors:  E Hollander; R Dolgoff-Kaspar; C Cartwright; R Rawitt; S Novotny
Journal:  J Clin Psychiatry       Date:  2001-07       Impact factor: 4.384

Review 5.  New directions in the treatment of autism spectrum disorders from animal model research.

Authors:  Kathryn K Chadman; Sara R Guariglia; Jiyeon Helen Yoo
Journal:  Expert Opin Drug Discov       Date:  2012-04-12       Impact factor: 6.098

6.  A pilot study of D-cycloserine in subjects with autistic disorder.

Authors:  David J Posey; Deborah L Kem; Naomi B Swiezy; Thayne L Sweeten; Ryan E Wiegand; Christopher J McDougle
Journal:  Am J Psychiatry       Date:  2004-11       Impact factor: 18.112

7.  Comorbid psychiatric disorders in children with autism: interview development and rates of disorders.

Authors:  Ovsanna T Leyfer; Susan E Folstein; Susan Bacalman; Naomi O Davis; Elena Dinh; Jubel Morgan; Helen Tager-Flusberg; Janet E Lainhart
Journal:  J Autism Dev Disord       Date:  2006-10

8.  Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders.

Authors:  Adam J Guastella; Stewart L Einfeld; Kylie M Gray; Nicole J Rinehart; Bruce J Tonge; Timothy J Lambert; Ian B Hickie
Journal:  Biol Psychiatry       Date:  2009-11-07       Impact factor: 13.382

Review 9.  The use of selective serotonin reuptake inhibitors in autism and related disorders.

Authors:  David J Posey; Craig A Erickson; Kimberly A Stigler; Christopher J McDougle
Journal:  J Child Adolesc Psychopharmacol       Date:  2006 Feb-Apr       Impact factor: 2.576

10.  A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder.

Authors:  Ronald N Marcus; Randall Owen; Lisa Kamen; George Manos; Robert D McQuade; William H Carson; Michael G Aman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2009-11       Impact factor: 8.829

View more
  27 in total

1.  The Need for a Developmentally Based Measure of Social Communication Skills.

Authors:  Somer Bishop; Cristan Farmer; Aaron Kaat; Stelios Georgiades; Stephen Kanne; Audrey Thurm
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-06       Impact factor: 8.829

2.  12-week, placebo-controlled trial of add-on riluzole in the treatment of childhood-onset obsessive-compulsive disorder.

Authors:  Paul J Grant; Lisa A Joseph; Cristan A Farmer; David A Luckenbaugh; Lorraine C Lougee; Carlos A Zarate; Susan E Swedo
Journal:  Neuropsychopharmacology       Date:  2013-12-19       Impact factor: 7.853

3.  Autism Spectrum Disorder in Fragile X Syndrome: Cooccurring Conditions and Current Treatment.

Authors:  Walter E Kaufmann; Sharon A Kidd; Howard F Andrews; Dejan B Budimirovic; Amy Esler; Barbara Haas-Givler; Tracy Stackhouse; Catharine Riley; Georgina Peacock; Stephanie L Sherman; W Ted Brown; Elizabeth Berry-Kravis
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

4.  Using the Clinical Global Impression scale to assess social communication change in minimally verbal children with autism spectrum disorder.

Authors:  Christina Toolan; Alison Holbrook; Andrew Schlink; Stephanie Shire; Nancy Brady; Connie Kasari
Journal:  Autism Res       Date:  2021-11-19       Impact factor: 5.216

Review 5.  Memantine for autism spectrum disorder.

Authors:  Amanda Brignell; Catherine Marraffa; Katrina Williams; Tamara May
Journal:  Cochrane Database Syst Rev       Date:  2022-08-25

6.  Safety and Efficacy of Medical Cannabis in Autism Spectrum Disorder Compared with Commonly Used Medications.

Authors:  Richard Holdman; Daniel Vigil; Kelsey Robinson; Puja Shah; Alexandra Elyse Contreras
Journal:  Cannabis Cannabinoid Res       Date:  2021-08-24

7.  Modulation of resting-state amygdala-frontal functional connectivity by oxytocin in generalized social anxiety disorder.

Authors:  Sonam Dodhia; Avinash Hosanagar; Daniel A Fitzgerald; Izelle Labuschagne; Amanda G Wood; Pradeep J Nathan; K Luan Phan
Journal:  Neuropsychopharmacology       Date:  2014-03-05       Impact factor: 7.853

8.  Effects of propranolol on conversational reciprocity in autism spectrum disorder: a pilot, double-blind, single-dose psychopharmacological challenge study.

Authors:  Rachel M Zamzow; Bradley J Ferguson; Janine P Stichter; Eric C Porges; Alexandra S Ragsdale; Morgan L Lewis; David Q Beversdorf
Journal:  Psychopharmacology (Berl)       Date:  2016-01-14       Impact factor: 4.530

9.  Bumetanide Oral Liquid Formulation for the Treatment of Children and Adolescents with Autism Spectrum Disorder: Design of Two Phase III Studies (SIGN Trials).

Authors:  Véronique Crutel; Estelle Lambert; Pierre-François Penelaud; Cristina Albarrán Severo; Joaquin Fuentes; Antoine Rosier; Amaia Hervás; Stéphane Marret; Guiomar Oliveira; Mara Parellada; Simon Kyaga; Sylvie Gouttefangeas; Marianne Bertrand; Denis Ravel; Bruno Falissard
Journal:  J Autism Dev Disord       Date:  2021-08

Review 10.  Ketogenic Dietary Therapies in Patients with Autism Spectrum Disorder: Facts or Fads? A Scoping Review and a Proposal for a Shared Protocol.

Authors:  Costanza Varesio; Serena Grumi; Martina Paola Zanaboni; Martina Maria Mensi; Matteo Chiappedi; Ludovica Pasca; Cinzia Ferraris; Anna Tagliabue; Renato Borgatti; Valentina De Giorgis
Journal:  Nutrients       Date:  2021-06-16       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.